[{"id":"6067170a-b400-4596-b990-2bd8229909eb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04782193","created_at":"2021-03-04T12:52:22.373Z","updated_at":"2024-07-02T16:35:50.281Z","phase":"Phase 1/2","brief_title":"a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma","source_id_and_acronym":"NCT04782193","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" IL6 • CD22 • IL10","pipe":" | ","alterations":" CD19 expression • CD22 positive • CD22 expression • IL10 elevation","tags":["IL6 • CD22 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • CD22 positive • CD22 expression • IL10 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 and CD22 targeted prime CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/23/2021","start_date":" 05/23/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-04-18"}]